Respiratory drugs and devices companies are concentrating on developing new products. Companies are expanding their product portfolios and increasing their R&D budget. Major respiratory devices include therapeutic devices such as masks, ventilators, humidifiers, positive airway pressure devices and other devices. Other respiratory devices include diagnostic and monitoring devices and consumables and accessories meters. Respiratory drugs segmented on the basis of route of administration and drugs class.
For Related Reports: Medical Devices Industry
The regional outlook of global respiratory drugs and devices market includes: North America, Europe, APAC, and Rest of the world. North America is the leading market. The market is expected to grow at a stable CAGR. North American market is driven by high sales of branded drugs and a high number of patient diagnosed and treated for respiratory diseases. North American marker is followed by Europe, Asia Pacific and Rest of the world. Asia Pacific market is expected to have highest CAGR amongst all regions for the forecasted period of 2018-2023. APAC market is driven by growing aging population with respiratory disorders. Pollution and lifestyle changes are also driving the APAC market.
Key Companies in the global respiratory drugs and devices market include GE Healthcare, Philips Healthcare, Roche, Merck & Co., GlaxoSmithKline, Baxter International, and 97 others.
Global respiratory drugs and devices market by therapeutic devices
Global respiratory drugs and devices market by respiratory drugs
Global respiratory drugs and devices market by end users
The market study of respiratory drugs and devices market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases
Whitepapers, research-papers and news blogs
Company websites and their product catalogue.
The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis, Porter five analysis delivering insights into the market for better business decisions.
The Report Covers:
Comprehensive research methodology of Global respiratory drugs and devices Market.
This report also includes detailed and extensive market overview with Analyst insights & key market trends.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global respiratory drugs and devices Market.
Insights about market determinants which are stimulating the Global respiratory drugs and devices Market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.3. Gap Analysis
2.4. Historical Analysis
2.5. Current Market Trends
2.6.1. Tax Laws
126.96.36.199. United States
188.8.131.52. European Union
184.108.40.206. Rest of the World
2.6.2. Drug and Device Regulations
220.127.116.11. United States
18.104.22.168. European Union
22.214.171.124. Rest of the World
2.7. Respiratory Diseases
2.7.2. Copd (Chronic Obstructive Pulmonary Disease)
2.7.3. Cystic Fibrosis
2.7.4. Chronic Bronchitis
2.7.6. Allergic Rhinitis
3. Market Determinant
3.1.1. Predominance of Chronic Respiratory Diseases Such As Asthma
3.1.2. Overgrowing Geriatric Population Base Are More Prone To Respiratory Diseases
3.1.3. Changing Lifestyle Coupled With Rise In Obesity
3.1.4. Innovations and Development of New Products
3.2.1. Reimbursements and Strict Government Regulations In Emerging Markets
3.2.2. High Price
3.2.3. Limited Awareness and Availability In Emerging Markets
3.3.1. Growing Demand For Remote Monitoring and Home Care Products
3.3.2. Emerging Markets
4. Market Segmentation
4.1. Respiratory Drugs and Devices By Product
4.1.1. Respiratory Therapeutic Devices
126.96.36.199. Respiratory Positive Airway Pressure Devices
188.8.131.52.1. Respiratory Continuous Positive Airway Pressure (Cpap) Devices
184.108.40.206.2. Respiratory Automatic Pap (Apap) Devices
220.127.116.11.3. Respiratory Bi-Level Pap (Bpap) Devices
18.104.22.168. Respiratory Masks
22.214.171.124.1. Respiratory Nasal Masks
126.96.36.199.2. Respiratory Full-Face Masks
188.8.131.52.3. Respiratory Nasal Pillow Masks
184.108.40.206.4. Respiratory Oral Masks
220.127.116.11. Respiratory Ventilators
18.104.22.168.1. Respiratory Adult Ventilators
22.214.171.124.2. Respiratory Infant/Neonatal Ventilators
126.96.36.199. Respiratory Nebulizers
188.8.131.52. Respiratory Humidifiers
184.108.40.206.1. Respiratory Heated Humidifiers
220.127.116.11.2. Respiratory Passover Humidifiers
18.104.22.168. Respiratory Oxygen Concentrators
22.214.171.124.1. Respiratory Fixed Oxygen Concentrators
126.96.36.199.2. Respiratory Portable Oxygen Concentrators
188.8.131.52. Respiratory Inhalers
184.108.40.206.1. Respiratory Dry Powder Inhalers (Dpis)
220.127.116.11.2. Respiratory Metered Dose Inhalers
18.104.22.168. Respiratory Reusable Resuscitators
22.214.171.124.1. Respiratory Adult Resuscitators
126.96.36.199.2. Respiratory Infant/Neonatal Resuscitators
188.8.131.52. Respiratory Nitric Oxide Delivery Units
184.108.40.206. Respiratory Oxygen Hoods
4.1.2. Respiratory Diagnostic and Monitoring Devices
220.127.116.11. Respiratory Pulse Oximeters
18.104.22.168.1. Respiratory Pulse Oximeter Sensors
22.214.171.124.2. Respiratory Pulse Oximeter Equipment
126.96.36.199. Respiratory Capnographs
188.8.131.52. Respiratory Gas Analyzers
184.108.40.206. Respiratory Spirometers
220.127.116.11. Respiratory Polysomnography (Psg) Devices
18.104.22.168. Respiratory Peak Flow Meters
4.1.3. Respiratory Consumables and Accessories Meters
22.214.171.124. Respiratory Disposable Masks Meters
126.96.36.199. Respiratory Disposable Resuscitators Meters
188.8.131.52. Respiratory Tracheostomy Tubes Meters
184.108.40.206. Respiratory Nasal Cannulas Meters
220.127.116.11. Respiratory Other Consumables and Accessories Meters
4.2. Respiratory Drugs and Devices By Respiratory Drugs
4.2.1. Respiratory Drugs By Route of Administration
18.104.22.168. Oral Respiratory Drugs
22.214.171.124. Injectable Respiratory Drugs
126.96.36.199. Inhalable Respiratory Drugs
4.2.2. Respiratory Drugs By Drug Class
188.8.131.52. Beta2 Agonists
184.108.40.206. Antiasthmatic Combinations
220.127.116.11. Leukotriene Inhibitors
18.104.22.168. Mast Cell Stabilizers
22.214.171.124. Phosphodiesterase 4 (Pde4) Inhibitors
126.96.36.199. Other Respiratory Drugs
4.3. Respiratory Drugs and Devices By End Users
4.3.2. Home Care
4.3.3. Other End Users
5. Competitive Landscape
5.1. Key Strategy Analysis
5.2. Key Company Analysis
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.3. Rest of North America
6.2.1. United Kingdom
6.2.6. Rest of Europe
6.3. Asia Pacific
6.4. Rest of the World
7. Company Profiles
7.2. Adamis (Admp)
7.3. Ads Biotechnology
7.4. Air Liquide
7.5. Alios Biopharma Inc.
7.6. Alung Technologies
7.9. Applied Biocode Inc
7.10. Aptimmune Biologics Inc
7.13. Aros Pharma Aps
7.14. Arrow Therapeutics, Ltd.
7.15. Avita Medical
7.16. Baxter International
7.17. Bayer Ag
7.18. Beximco Pharmaceuticals Ltd
7.19. Biomarck Pharmaceuticals, Ltd
7.20. Bioxydyn Limited
7.21. Boehringer Ingelheim
7.22. Capellon Pharmaceuticals, Ltd.
7.23. Chart Industries
7.24. Chiesi Farmaceutici S.P.A
7.27. Civitas Therapeutics, Inc.
7.28. Compumedics Limited
7.29. Covidien Plc
7.30. Dainippon Sumitomo Pharma Co., Ltd.
7.31. Drager Medical Gmbh
7.32. Edimer Pharmaceuticals
7.33. Edixomed Ltd.
7.34. Enanta Pharmaceuticals
7.36. Fisher and Paykel Healthcare Corp. Ltd
7.37. Ge Healthcare Limited
7.38. Gecko Health Innovations, Inc.
7.39. Gilbert Technologies
7.40. Gilead Sciences, Inc.
7.43. H&T Presspart
7.44. Hamilton Medical Ag
7.45. Invacare Corporation
7.46. Merck and Co.
7.47. Meridian Bioscience
7.49. Microbot Medical
7.51. Nabriva Therapeutics
7.52. Nephron Pharmaceuticals Corporation
7.55. Novartis Ag
7.56. Nox Medical
7.57. Oncolytics Biotech
7.58. Opko Health
7.60. Orion Corporation
7.61. Otsuka Pharmaceuticals
7.62. Oxagen Limited
7.64. Palobiofarma Sl
7.65. Patara Pharma
7.66. Pathway Therapeutics Ltd
7.71. Philips Healthcare
7.72. Pieris Pharmaceuticals
7.73. Plair Sa
7.74. Pmd Solutions
7.75. Pneumacare Limited
7.76. Propeller Health
7.77. Pulmotect, Inc.
7.81. Respiratory Motion
7.82. Roche Diagnostics
7.83. Savara Inc.
7.84. Sime Diagnostics Ltd
7.85. Sunovion Pharmaceuticals Inc
7.87. Synapse Biomedical
7.88. Takeda Pharmaceutical Company Limited,
7.89. Techno Drugs Ltd.
7.90. Teicos Pharma Oy
7.91. Teijin Pharma Ltd.
7.92. Teva Pharmaceuticals
7.93. Totalcare Ehealth
7.94. Valeant Pharmaceuticals
7.96. Ventirx Pharmaceuticals, Inc.
7.97. Verona Pharma Plc
7.98. Vertex Pharmaceuticals
7.99. Vida Therapeutics Inc.
7.100. Virionhealth Limited
7.101. Viroblock Sa
7.102. Viroclinics Biosciences B.V.
7.103. Windtree Therapeutics
- Adamis (Admp)
- Ads Biotechnology
- Air Liquide
- Alios Biopharma Inc.
- Alung Technologies
- Applied Biocode Inc
- Aptimmune Biologics Inc
- Aros Pharma Aps
- Arrow Therapeutics, Ltd.
- Avita Medical
- Baxter International
- Bayer Ag
- Beximco Pharmaceuticals Ltd
- Biomarck Pharmaceuticals, Ltd
- Bioxydyn Limited
- Boehringer Ingelheim
- Capellon Pharmaceuticals, Ltd.
- Chart Industries
- Chiesi Farmaceutici S.P.A
- Civitas Therapeutics, Inc.
- Compumedics Limited
- Covidien Plc
- Dainippon Sumitomo Pharma Co., Ltd.
- Drager Medical Gmbh
- Edimer Pharmaceuticals
- Edixomed Ltd.
- Enanta Pharmaceuticals
- Fisher And Paykel Healthcare Corp. Ltd
- Ge Healthcare Limited
- Gecko Health Innovations, Inc.
- Gilbert Technologies
- Gilead Sciences, Inc.
- H&T Presspart
- Hamilton Medical Ag
- Invacare Corporation
- Merck And Co.
- Meridian Bioscience
- Microbot Medical
- Nabriva Therapeutics
- Nephron Pharmaceuticals Corporation
- Novartis Ag
- Nox Medical
- Oncolytics Biotech
- Opko Health
- Orion Corporation
- Otsuka Pharmaceuticals
- Oxagen Limited
- Palobiofarma Sl
- Patara Pharma
- Pathway Therapeutics Ltd
- Philips Healthcare
- Pieris Pharmaceuticals
- Plair Sa
- Pmd Solutions
- Pneumacare Limited
- Propeller Health
- Pulmotect, Inc.
- Respiratory Motion
- Roche Diagnostics
- Savara Inc.
- Sime Diagnostics Ltd
- Sunovion Pharmaceuticals Inc
- Synapse Biomedical
- Takeda Pharmaceutical Company Limited,
- Techno Drugs Ltd.
- Teicos Pharma Oy
- Teijin Pharma Ltd.
- Teva Pharmaceuticals
- Totalcare Ehealth
- Valeant Pharmaceuticals
- Ventirx Pharmaceuticals, Inc.
- Verona Pharma Plc
- Vertex Pharmaceuticals
- Vida Therapeutics Inc.
- Virionhealth Limited
- Viroblock Sa
- Viroclinics Biosciences B.V.
- Windtree Therapeutics